Submit your email to push it up the queue
Ambry Genetics Corporation, a leading player in the genetic testing industry, is headquartered in the United States. Founded in 2004, the company has established itself as a pioneer in clinical genetic testing, focusing on hereditary cancer, cardiovascular conditions, and other genetic disorders. With a commitment to advancing precision medicine, Ambry offers a comprehensive suite of services, including next-generation sequencing and innovative diagnostic solutions that set it apart in the market. Ambry's unique approach to genetic testing combines cutting-edge technology with a robust clinical database, enabling healthcare providers to make informed decisions for patient care. The company has achieved significant milestones, including numerous partnerships with healthcare institutions and a strong reputation for accuracy and reliability. As a trusted name in genetic diagnostics, Ambry Genetics continues to shape the future of personalised medicine.
How does Ambry Genetics Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ambry Genetics Corporation's score of 72 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ambry Genetics Corporation, headquartered in the US, currently does not have specific carbon emissions data available for recent years. As a current subsidiary of Konica Minolta, Inc., any climate commitments or emissions data would be inherited from this parent organisation. Ambry Genetics has not publicly disclosed any specific reduction targets or achievements related to carbon emissions. However, it is important to note that the climate initiatives and targets from Konica Minolta, Inc. may influence Ambry's sustainability strategies. These initiatives include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are aimed at reducing carbon footprints and promoting renewable energy usage. As of now, Ambry Genetics Corporation's climate commitments remain vague, with no detailed emissions data or specific reduction targets outlined. The company may benefit from the broader sustainability goals set by its parent company, which could guide its future climate actions.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|
Scope 1 | 167,360,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | - | - | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 1,030,177,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ambry Genetics Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.